HEADER TRANSFERASE 14-MAY-12 4AU8 TITLE CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5, SHOWING AN TITLE 2 UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE COMPND MOL_ID: 1; COMPND 2 MOLECULE: CYCLIN-DEPENDENT KINASE 5; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: RESIDUES 2-292; COMPND 5 SYNONYM: CELL DIVISION PROTEIN KINASE 5, SERINE/THREONINE-PROTEIN COMPND 6 KINASE PSSALRE, TAU PROTEIN KINASE II CATALYTIC SUBUNIT, TPKII COMPND 7 CATALYTIC SUBUNIT; COMPND 8 EC: 2.7.11.22; COMPND 9 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 8 EXPRESSION_SYSTEM_CELL_LINE: SF9; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PFASTBACHTB KEYWDS TRANSFERASE, CDK2, ALZHEIMER DISEASE EXPDTA X-RAY DIFFRACTION AUTHOR J.MALMSTROM,J.VIKLUND,C.SLIVO,A.COSTA,M.MAUDET,C.SANDELIN,G.HILLER, AUTHOR 2 L.L.OLSSON,A.AAGAARD,S.GESCHWINDNER,Y.XUE,M.VASANGE REVDAT 2 01-MAY-24 4AU8 1 REMARK REVDAT 1 27-MAR-13 4AU8 0 JRNL AUTH J.MALMSTROM,J.VIKLUND,C.SLIVO,A.COSTA,M.MAUDET,C.SANDELIN, JRNL AUTH 2 G.HILLER,L.L.OLSSON,A.AAGAARD,S.GESCHWINDNER,Y.XUE,M.VASANGE JRNL TITL SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP OF JRNL TITL 2 4-(1,3-BENZOTHIAZOL-2-YL)-THIOPHENE-2-SULFONAMIDES AS JRNL TITL 3 CYCLIN-DEPENDENT KINASE 5 (CDK5)/P25 INHIBITORS. JRNL REF BIOORG.MED.CHEM.LETT. V. 22 5919 2012 JRNL REFN ISSN 0960-894X JRNL PMID 22889803 JRNL DOI 10.1016/J.BMCL.2012.07.068 REMARK 2 REMARK 2 RESOLUTION. 1.90 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.1 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.90 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 47.94 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.2 REMARK 3 NUMBER OF REFLECTIONS : 53604 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.197 REMARK 3 R VALUE (WORKING SET) : 0.196 REMARK 3 FREE R VALUE : 0.234 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.090 REMARK 3 FREE R VALUE TEST SET COUNT : 2726 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.90 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.95 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.22 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 3841 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2859 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 3654 REMARK 3 BIN R VALUE (WORKING SET) : 0.2826 REMARK 3 BIN FREE R VALUE : 0.3534 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.87 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 187 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4443 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 71 REMARK 3 SOLVENT ATOMS : 474 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 27.23 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 33.17 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -4.01690 REMARK 3 B22 (A**2) : -4.01690 REMARK 3 B33 (A**2) : 8.03380 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.219 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.153 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.141 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.143 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.136 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.938 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.919 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 4619 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 6250 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1602 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 108 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 652 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 4619 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 567 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 5591 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.02 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.12 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 18.42 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4AU8 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 14-MAY-12. REMARK 100 THE DEPOSITION ID IS D_1290052485. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 11-DEC-08 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.4 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-4 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.94 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 53688 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.900 REMARK 200 RESOLUTION RANGE LOW (A) : 47.950 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.4 REMARK 200 DATA REDUNDANCY : 5.100 REMARK 200 R MERGE (I) : 0.08000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 16.5000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.90 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.95 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.9 REMARK 200 DATA REDUNDANCY IN SHELL : 4.00 REMARK 200 R MERGE FOR SHELL (I) : 0.44000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.100 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: UNPUBLISHED CDK5 COMPLEX REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 51.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.50 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 5.4 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 41 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z+1/2 REMARK 290 3555 -Y+1/2,X+1/2,Z+1/4 REMARK 290 4555 Y+1/2,-X+1/2,Z+3/4 REMARK 290 5555 -X+1/2,Y+1/2,-Z+1/4 REMARK 290 6555 X+1/2,-Y+1/2,-Z+3/4 REMARK 290 7555 Y,X,-Z REMARK 290 8555 -Y,-X,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 95.88300 REMARK 290 SMTRY1 3 0.000000 -1.000000 0.000000 41.63550 REMARK 290 SMTRY2 3 1.000000 0.000000 0.000000 41.63550 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 47.94150 REMARK 290 SMTRY1 4 0.000000 1.000000 0.000000 41.63550 REMARK 290 SMTRY2 4 -1.000000 0.000000 0.000000 41.63550 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 143.82450 REMARK 290 SMTRY1 5 -1.000000 0.000000 0.000000 41.63550 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 41.63550 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 47.94150 REMARK 290 SMTRY1 6 1.000000 0.000000 0.000000 41.63550 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 41.63550 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 143.82450 REMARK 290 SMTRY1 7 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY2 7 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 95.88300 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2710 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 25480 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -95.9 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH A2105 LIES ON A SPECIAL POSITION. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -3 REMARK 465 ALA A -2 REMARK 465 MET A -1 REMARK 465 ARG A 36 REMARK 465 LEU A 37 REMARK 465 ASP A 38 REMARK 465 ASP A 39 REMARK 465 ASP A 40 REMARK 465 ASP A 41 REMARK 465 GLU A 42 REMARK 465 GLY A 43 REMARK 465 VAL A 44 REMARK 465 SER A 72 REMARK 465 ASP A 73 REMARK 465 LYS A 74 REMARK 465 CYS A 157 REMARK 465 TYR A 158 REMARK 465 CYS A 290 REMARK 465 PRO A 291 REMARK 465 PRO A 292 REMARK 465 GLY B -3 REMARK 465 ALA B -2 REMARK 465 MET B -1 REMARK 465 GLY B 0 REMARK 465 SER B 1 REMARK 465 ASP B 38 REMARK 465 ASP B 39 REMARK 465 ASP B 40 REMARK 465 ASP B 41 REMARK 465 ASP B 73 REMARK 465 ARG B 156 REMARK 465 CYS B 157 REMARK 465 TYR B 158 REMARK 465 SER B 159 REMARK 465 ALA B 160 REMARK 465 GLU B 161 REMARK 465 CYS B 290 REMARK 465 PRO B 291 REMARK 465 PRO B 292 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A 125 -7.77 73.07 REMARK 500 ASP A 144 77.01 64.95 REMARK 500 ASP A 288 45.07 -90.25 REMARK 500 ARG B 125 -7.91 75.60 REMARK 500 ASP B 144 80.09 66.30 REMARK 500 LEU B 267 55.23 -92.81 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2003 DISTANCE = 5.96 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 1290 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 1291 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 1292 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE Z3R A 1293 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 1290 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 1291 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 1292 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE Z3R B 1293 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC9 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IMD B 1294 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1H4L RELATED DB: PDB REMARK 900 STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX REMARK 900 RELATED ID: 1LFR RELATED DB: PDB REMARK 900 THEORETICAL STRUCTURE OF HUMAN-CYCLIN DEPENDENT KINASE 5 (CDK5) REMARK 900 RELATED ID: 1UNG RELATED DB: PDB REMARK 900 STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE, REMARK 900 ALOISINE AND INDIRUBIN. REMARK 900 RELATED ID: 1UNH RELATED DB: PDB REMARK 900 STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE, REMARK 900 ALOISINE AND INDIRUBIN. REMARK 900 RELATED ID: 1UNL RELATED DB: PDB REMARK 900 STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE REMARK 900 ROSCOVITINE, ALOISINE AND INDIRUBIN. DBREF 4AU8 A 2 292 UNP Q00535 CDK5_HUMAN 2 292 DBREF 4AU8 B 2 292 UNP Q00535 CDK5_HUMAN 2 292 SEQADV 4AU8 GLY A -3 UNP Q00535 EXPRESSION TAG SEQADV 4AU8 ALA A -2 UNP Q00535 EXPRESSION TAG SEQADV 4AU8 MET A -1 UNP Q00535 EXPRESSION TAG SEQADV 4AU8 GLY A 0 UNP Q00535 EXPRESSION TAG SEQADV 4AU8 SER A 1 UNP Q00535 EXPRESSION TAG SEQADV 4AU8 GLY B -3 UNP Q00535 EXPRESSION TAG SEQADV 4AU8 ALA B -2 UNP Q00535 EXPRESSION TAG SEQADV 4AU8 MET B -1 UNP Q00535 EXPRESSION TAG SEQADV 4AU8 GLY B 0 UNP Q00535 EXPRESSION TAG SEQADV 4AU8 SER B 1 UNP Q00535 EXPRESSION TAG SEQRES 1 A 296 GLY ALA MET GLY SER GLN LYS TYR GLU LYS LEU GLU LYS SEQRES 2 A 296 ILE GLY GLU GLY THR TYR GLY THR VAL PHE LYS ALA LYS SEQRES 3 A 296 ASN ARG GLU THR HIS GLU ILE VAL ALA LEU LYS ARG VAL SEQRES 4 A 296 ARG LEU ASP ASP ASP ASP GLU GLY VAL PRO SER SER ALA SEQRES 5 A 296 LEU ARG GLU ILE CYS LEU LEU LYS GLU LEU LYS HIS LYS SEQRES 6 A 296 ASN ILE VAL ARG LEU HIS ASP VAL LEU HIS SER ASP LYS SEQRES 7 A 296 LYS LEU THR LEU VAL PHE GLU PHE CYS ASP GLN ASP LEU SEQRES 8 A 296 LYS LYS TYR PHE ASP SER CYS ASN GLY ASP LEU ASP PRO SEQRES 9 A 296 GLU ILE VAL LYS SER PHE LEU PHE GLN LEU LEU LYS GLY SEQRES 10 A 296 LEU GLY PHE CYS HIS SER ARG ASN VAL LEU HIS ARG ASP SEQRES 11 A 296 LEU LYS PRO GLN ASN LEU LEU ILE ASN ARG ASN GLY GLU SEQRES 12 A 296 LEU LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY SEQRES 13 A 296 ILE PRO VAL ARG CYS TYR SER ALA GLU VAL VAL THR LEU SEQRES 14 A 296 TRP TYR ARG PRO PRO ASP VAL LEU PHE GLY ALA LYS LEU SEQRES 15 A 296 TYR SER THR SER ILE ASP MET TRP SER ALA GLY CYS ILE SEQRES 16 A 296 PHE ALA GLU LEU ALA ASN ALA GLY ARG PRO LEU PHE PRO SEQRES 17 A 296 GLY ASN ASP VAL ASP ASP GLN LEU LYS ARG ILE PHE ARG SEQRES 18 A 296 LEU LEU GLY THR PRO THR GLU GLU GLN TRP PRO SER MET SEQRES 19 A 296 THR LYS LEU PRO ASP TYR LYS PRO TYR PRO MET TYR PRO SEQRES 20 A 296 ALA THR THR SER LEU VAL ASN VAL VAL PRO LYS LEU ASN SEQRES 21 A 296 ALA THR GLY ARG ASP LEU LEU GLN ASN LEU LEU LYS CYS SEQRES 22 A 296 ASN PRO VAL GLN ARG ILE SER ALA GLU GLU ALA LEU GLN SEQRES 23 A 296 HIS PRO TYR PHE SER ASP PHE CYS PRO PRO SEQRES 1 B 296 GLY ALA MET GLY SER GLN LYS TYR GLU LYS LEU GLU LYS SEQRES 2 B 296 ILE GLY GLU GLY THR TYR GLY THR VAL PHE LYS ALA LYS SEQRES 3 B 296 ASN ARG GLU THR HIS GLU ILE VAL ALA LEU LYS ARG VAL SEQRES 4 B 296 ARG LEU ASP ASP ASP ASP GLU GLY VAL PRO SER SER ALA SEQRES 5 B 296 LEU ARG GLU ILE CYS LEU LEU LYS GLU LEU LYS HIS LYS SEQRES 6 B 296 ASN ILE VAL ARG LEU HIS ASP VAL LEU HIS SER ASP LYS SEQRES 7 B 296 LYS LEU THR LEU VAL PHE GLU PHE CYS ASP GLN ASP LEU SEQRES 8 B 296 LYS LYS TYR PHE ASP SER CYS ASN GLY ASP LEU ASP PRO SEQRES 9 B 296 GLU ILE VAL LYS SER PHE LEU PHE GLN LEU LEU LYS GLY SEQRES 10 B 296 LEU GLY PHE CYS HIS SER ARG ASN VAL LEU HIS ARG ASP SEQRES 11 B 296 LEU LYS PRO GLN ASN LEU LEU ILE ASN ARG ASN GLY GLU SEQRES 12 B 296 LEU LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY SEQRES 13 B 296 ILE PRO VAL ARG CYS TYR SER ALA GLU VAL VAL THR LEU SEQRES 14 B 296 TRP TYR ARG PRO PRO ASP VAL LEU PHE GLY ALA LYS LEU SEQRES 15 B 296 TYR SER THR SER ILE ASP MET TRP SER ALA GLY CYS ILE SEQRES 16 B 296 PHE ALA GLU LEU ALA ASN ALA GLY ARG PRO LEU PHE PRO SEQRES 17 B 296 GLY ASN ASP VAL ASP ASP GLN LEU LYS ARG ILE PHE ARG SEQRES 18 B 296 LEU LEU GLY THR PRO THR GLU GLU GLN TRP PRO SER MET SEQRES 19 B 296 THR LYS LEU PRO ASP TYR LYS PRO TYR PRO MET TYR PRO SEQRES 20 B 296 ALA THR THR SER LEU VAL ASN VAL VAL PRO LYS LEU ASN SEQRES 21 B 296 ALA THR GLY ARG ASP LEU LEU GLN ASN LEU LEU LYS CYS SEQRES 22 B 296 ASN PRO VAL GLN ARG ILE SER ALA GLU GLU ALA LEU GLN SEQRES 23 B 296 HIS PRO TYR PHE SER ASP PHE CYS PRO PRO HET SO4 A1290 5 HET SO4 A1291 5 HET SO4 A1292 5 HET Z3R A1293 18 HET SO4 B1290 5 HET SO4 B1291 5 HET SO4 B1292 5 HET Z3R B1293 18 HET IMD B1294 5 HETNAM SO4 SULFATE ION HETNAM Z3R 4-(1,3-BENZOTHIAZOL-2-YL)THIOPHENE-2-SULFONAMIDE HETNAM IMD IMIDAZOLE FORMUL 3 SO4 6(O4 S 2-) FORMUL 6 Z3R 2(C11 H8 N2 O2 S3) FORMUL 11 IMD C3 H5 N2 1+ FORMUL 12 HOH *474(H2 O) HELIX 1 1 GLY A 0 GLN A 2 5 3 HELIX 2 2 PRO A 45 LYS A 56 1 12 HELIX 3 3 LEU A 87 ASN A 95 1 9 HELIX 4 4 ASP A 99 ARG A 120 1 22 HELIX 5 5 LYS A 128 GLN A 130 5 3 HELIX 6 6 THR A 164 ARG A 168 5 5 HELIX 7 7 PRO A 169 PHE A 174 1 6 HELIX 8 8 THR A 181 ASN A 197 1 17 HELIX 9 9 ASP A 207 GLY A 220 1 14 HELIX 10 10 TRP A 227 LEU A 233 5 7 HELIX 11 11 SER A 247 VAL A 251 5 5 HELIX 12 12 ASN A 256 LEU A 267 1 12 HELIX 13 13 ASN A 270 ARG A 274 5 5 HELIX 14 14 SER A 276 GLN A 282 1 7 HELIX 15 15 HIS A 283 SER A 287 5 5 HELIX 16 16 GLU B 42 LYS B 56 1 15 HELIX 17 17 LEU B 87 SER B 93 1 7 HELIX 18 18 ASP B 99 ARG B 120 1 22 HELIX 19 19 LYS B 128 GLN B 130 5 3 HELIX 20 20 THR B 164 ARG B 168 5 5 HELIX 21 21 PRO B 169 PHE B 174 1 6 HELIX 22 22 THR B 181 ASN B 197 1 17 HELIX 23 23 ASP B 207 GLY B 220 1 14 HELIX 24 24 TRP B 227 LEU B 233 5 7 HELIX 25 25 SER B 247 VAL B 251 5 5 HELIX 26 26 ASN B 256 LEU B 267 1 12 HELIX 27 27 ASN B 270 ARG B 274 5 5 HELIX 28 28 SER B 276 GLN B 282 1 7 HELIX 29 29 HIS B 283 SER B 287 5 5 SHEET 1 AA 5 TYR A 4 GLU A 12 0 SHEET 2 AA 5 THR A 17 ASN A 23 -1 O VAL A 18 N ILE A 10 SHEET 3 AA 5 ILE A 29 VAL A 35 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LEU A 76 GLU A 81 -1 O LEU A 76 N VAL A 35 SHEET 5 AA 5 LEU A 66 LEU A 70 -1 N HIS A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 132 ILE A 134 -1 O ILE A 134 N GLN A 85 SHEET 3 AB 3 LEU A 140 LEU A 142 -1 O LYS A 141 N LEU A 133 SHEET 1 AC 2 VAL A 122 LEU A 123 0 SHEET 2 AC 2 ARG A 149 ALA A 150 -1 O ARG A 149 N LEU A 123 SHEET 1 BA 5 TYR B 4 GLU B 12 0 SHEET 2 BA 5 THR B 17 ASN B 23 -1 O VAL B 18 N ILE B 10 SHEET 3 BA 5 ILE B 29 ARG B 36 -1 O VAL B 30 N ALA B 21 SHEET 4 BA 5 LYS B 75 PHE B 80 -1 O LEU B 76 N VAL B 35 SHEET 5 BA 5 LEU B 66 HIS B 71 -1 N HIS B 67 O VAL B 79 SHEET 1 BB 3 GLN B 85 ASP B 86 0 SHEET 2 BB 3 LEU B 132 ILE B 134 -1 O ILE B 134 N GLN B 85 SHEET 3 BB 3 LEU B 140 LEU B 142 -1 O LYS B 141 N LEU B 133 SHEET 1 BC 2 VAL B 122 LEU B 123 0 SHEET 2 BC 2 ARG B 149 ALA B 150 -1 O ARG B 149 N LEU B 123 SITE 1 AC1 10 ARG A 24 TRP A 227 PRO A 228 SER A 229 SITE 2 AC1 10 ASN A 270 VAL A 272 HOH A2218 HOH A2220 SITE 3 AC1 10 HOH A2251 HOH A2252 SITE 1 AC2 6 ARG A 50 ARG A 125 ARG A 149 PRO A 154 SITE 2 AC2 6 VAL A 155 ARG A 156 SITE 1 AC3 3 ARG A 120 HOH A2063 HOH A2064 SITE 1 AC4 10 ILE A 10 PHE A 80 CYS A 83 ASP A 84 SITE 2 AC4 10 GLN A 85 ASP A 86 LYS A 89 LEU A 133 SITE 3 AC4 10 ASP A 144 HOH A2089 SITE 1 AC5 8 GLN B 2 ARG B 24 TRP B 227 PRO B 228 SITE 2 AC5 8 SER B 229 ASN B 270 HOH B2174 HOH B2220 SITE 1 AC6 6 ARG B 50 ARG B 125 ARG B 149 PRO B 154 SITE 2 AC6 6 VAL B 155 HOH B2127 SITE 1 AC7 4 SER B 247 ARG B 260 HOH B2192 HOH B2199 SITE 1 AC8 10 ILE B 10 ALA B 31 CYS B 83 ASP B 84 SITE 2 AC8 10 GLN B 85 ASP B 86 LYS B 89 LEU B 133 SITE 3 AC8 10 ASP B 144 HOH B2077 SITE 1 AC9 4 TYR A 179 HOH A2152 CYS B 53 LYS B 56 CRYST1 83.271 83.271 191.766 90.00 90.00 90.00 P 41 21 2 16 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.012009 0.000000 0.000000 0.00000 SCALE2 0.000000 0.012009 0.000000 0.00000 SCALE3 0.000000 0.000000 0.005215 0.00000